Clik here to view.
Everest Medicines and Kezar Life Sciences Receive IND Approval from China...
SHANGHAI & SOUTH SAN FRANCISCO, Calif. Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National...
View ArticleClik here to view.
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
View ArticleClik here to view.
PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a...
BURLINGTON, Mass. PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven...
View ArticleClik here to view.
ReNAgade Therapeutics任命Joe Bolen博士为首席科学创新官
马萨诸塞州剑桥 (美国商业资讯)– 致力于释放RNA药物无限潜力的ReNAgade Therapeutics今天宣布任命MPM BioImpact执行合伙人、PureTech Health前首席科学官、Moderna Therapeutics前研发总裁Joe Bolen博士为公司首位首席科学创新官。 ReNAgade首席执行官Amit D....
View ArticleClik here to view.
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for full-year 2023, along with recent product highlights and corporate updates. “We made...
View ArticleClik here to view.
ReNAgadeセラピューティクス、ジョー・ボーレン氏を最高科学イノベーション責任者に任命
米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — RNA医薬品の開発で業界をリードするReNAgadeセラピューティクスは、MPMバイオインパクトのエグゼクティブ パートナーであり、ピュアテック・ヘルスの元最高科学責任者であり、モデルナ・セラピューティクス研究開発部門の元社長であるジョー・ボーレン氏を同社初の最高科学イノベーション責任者に任命したことを発表しました。...
View ArticleClik here to view.
ベイジーン、非小細胞肺がん治療薬チスレリズマブに対してCHMPから肯定的意見を受領
スイス・バーゼル、中国・北京、米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — がん領域専門のグローバル製薬企業ベイジーン（NASDAQ: BGNE; HKEX: 06160; SSE:...
View ArticleClik here to view.
BeiGene to Present at Upcoming Investor Conferences
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in...
View ArticleClik here to view.
ベイジーン、2023年第4・四半期および通期決算と事業に関する最新情報を発表
スイス・バーゼル、中国・北京、米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — がん領域専門のグローバル製薬企業であるベイジーン（NASDAQ: BGNE; HKEX: 06160; SSE:...
View ArticleClik here to view.
ImmunoScape Leadership to Present at Upcoming Industry Conferences
SAN DIEGO & SINGAPORE ImmunoScape, a biotechnology company focused on next-generation T Cell receptor (TCR)-based immunotherapies, today announced that members of its executive team will present...
View ArticleClik here to view.
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with...
TOKYO & MUNICH The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN)...
View ArticleClik here to view.
Toyoda Gosei Invests in Craif, Inc., a Startup Developing Urine Test Kits for...
KIYOSU, Japan Toyoda Gosei Co., Ltd.(TOKYO:7282), in its efforts to pioneer new businesses to resolve societal healthcare issues, has invested1 in Craif, Inc., a startup out of Nagoya University...
View ArticleClik here to view.
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second...
NEW YORK & SUZHOU, China AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, and Innovent Biologics,...
View ArticleClik here to view.
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical...
STRASBOURG, France & TOKYO & WALTHAM, Mass. Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC...
View ArticleClik here to view.
EpimAb Biotherapeutics to Present Late-breaking Abstract on Preclinical...
SHANGHAI EpimAb Biotherapeutics, a global clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce the acceptance of a late-breaking...
View ArticleClik here to view.
Zai Lab Announces Participation in March Investor Conference
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference...
View ArticleClik here to view.
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the final overall survival (OS) data from the Phase 3 randomized, double-blind, placebo-controlled...
View ArticleClik here to view.
Apollo Hospital in New Delhi Initiates First Non-Invasive ZAP-X Brain Tumor...
SAN CARLOS, Calif. ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Apollo Hospital in New Delhi, India, completed its first patient treatment...
View ArticleClik here to view.
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
View ArticleClik here to view.
Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study...
TOKUSHIMA, Japan Following to the previous information on Jan. 30th. in 2024, we are excited to share our latest development status. FDA submission of the protocol of the Phase I/II study of...
View Article